Literature DB >> 15006908

Pap screening in a U.S. health plan.

Ralph P Insinga1, Andrew G Glass, Brenda B Rush.   

Abstract

The U.S. Preventive Services Task Force recommends cervical cancer screening begin with the onset of sexual activity and be repeated at least every 3 years until age 65. Previous studies examining the annual utilization and frequency of Pap screening have relied on patient self-report, found to be less reliable than medical records and administrative data. We estimate the age-specific rate and frequency of Pap screening in a U.S. health plan using 1998-2002 administrative data on 150,052 female enrollees within the Kaiser Permanente Northwest health plan, Portland, OR. We analyze the age-specific rate of cervical and vaginal Pap screening and age-specific proportion of routinely screened women receiving cervical screening at various yearly intervals. Of the enrolled women, 31.2% received a Pap smear in 1998, with utilization highest for ages 25-29 (62.4%). Among routinely screened women, 36% were estimated to receive annual cervical smears, versus 22% biennial, 13% triennial, and 29% less frequent screening. Less frequent screening was observed with increasing age. These are the first age-specific estimates of Pap screening frequency and annual utilization in a general healthcare setting, derived from administrative data, rather than self-report. Overall Pap utilization was lower than found in national surveys based on self-report. Despite limited evidence of benefit from more frequent screening, a substantially higher proportion of women was found to receive annual rather than either biennial or triennial screening. Sporadic screening was also more prevalent than expected based on prior self-reported data. Further opportunities exist for improving screening adherence, even within traditionally less vulnerable populations.

Entities:  

Mesh:

Year:  2004        PMID: 15006908

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  16 in total

1.  Cervical cancer screening in the United States and the Netherlands: a tale of two countries.

Authors:  Dik Habbema; Inge M C M De Kok; Martin L Brown
Journal:  Milbank Q       Date:  2012-03       Impact factor: 4.911

2.  Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples.

Authors:  Akhila Balasubramanian; Shalini L Kulasingam; Atar Baer; James P Hughes; Evan R Myers; Constance Mao; Nancy B Kiviat; Laura A Koutsky
Journal:  J Low Genit Tract Dis       Date:  2010-07       Impact factor: 1.925

Review 3.  Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Harms of cervical cancer screening in the United States and the Netherlands.

Authors:  Dik Habbema; Sheila Weinmann; Marc Arbyn; Aruna Kamineni; Andrew E Williams; Inge M C M de Kok; Folkert van Kemenade; Terry S Field; Joost van Rosmalen; Martin L Brown
Journal:  Int J Cancer       Date:  2017-03-01       Impact factor: 7.396

5.  The quality of preventive health care delivered to adults: results from a cross-sectional study in Southern Italy.

Authors:  Benedetto Manuti; Paolo Rizza; Aida Bianco; Carmelo G A Nobile; Maria Pavia
Journal:  BMC Public Health       Date:  2010-06-18       Impact factor: 3.295

6.  Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.

Authors:  Jane J Kim; Jesse Ortendahl; Sue J Goldie
Journal:  Ann Intern Med       Date:  2009-10-20       Impact factor: 25.391

7.  Translation of an efficacious cancer-screening intervention to women enrolled in a Medicaid managed care organization.

Authors:  Allen J Dietrich; Jonathan N Tobin; Andrea Cassells; Christina M Robinson; Meredith Reh; Karen A Romero; Ann Barry Flood; Michael L Beach
Journal:  Ann Fam Med       Date:  2007 Jul-Aug       Impact factor: 5.166

Review 8.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

9.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  BMJ       Date:  2009-10-08

10.  Model for assessing human papillomavirus vaccination strategies.

Authors:  Elamin H Elbasha; Erik J Dasbach; Ralph P Insinga
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.